MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Danaher Corp

Closed

SectorHealthcare

197.94 -3.52

Overview

Share price change

24h

Current

Min

197.71

Max

204.96

Key metrics

By Trading Economics

Income

268M

1.1B

Sales

738M

6.5B

P/E

Sector Avg

38.752

63.778

EPS

2.14

Dividend yield

0.62

Profit margin

16.611

Employees

61,000

EBITDA

-230M

1.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+28.05% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.62%

2.39%

Next Earnings

22 Apr 2025

Next Dividend date

25 Apr 2025

Market Stats

By TradingEconomics

Market Cap

-16B

147B

Previous open

201.46

Previous close

197.94

News Sentiment

By Acuity

33%

67%

106 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Danaher Corp Chart

Past performance is not a reliable indicator of future results.

Related News

5 Feb 2025, 12:54 UTC

Earnings

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 Jan 2025, 11:44 UTC

Earnings

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 Oct 2024, 10:35 UTC

Earnings

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23 Jul 2024, 10:55 UTC

Earnings

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29 Jan 2025, 15:25 UTC

Market Talk
Earnings

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 Jan 2025, 13:56 UTC

Top News
Earnings

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 Jan 2025, 11:08 UTC

Earnings

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 Jan 2025, 11:07 UTC

Earnings

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 Jan 2025, 11:07 UTC

Earnings

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 Jan 2025, 11:02 UTC

Earnings

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 Jan 2025, 11:01 UTC

Earnings

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 Jan 2025, 11:01 UTC

Earnings

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Net $1.09B >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q EPS $1.49 >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Adj EPS $2.14 >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Sales $6.5B >DHR

22 Oct 2024, 10:02 UTC

Earnings

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 Oct 2024, 10:02 UTC

Earnings

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22 Oct 2024, 10:01 UTC

Earnings

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22 Oct 2024, 10:00 UTC

Earnings

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22 Oct 2024, 10:00 UTC

Earnings

Danaher 3Q Sales $5.8B >DHR

22 Oct 2024, 10:00 UTC

Earnings

Danaher 3Q EPS $1.12 >DHR

22 Oct 2024, 10:00 UTC

Earnings

Danaher 3Q Adj EPS $1.71 >DHR

22 Oct 2024, 10:00 UTC

Earnings

Danaher 3Q Net $818M >DHR

22 Oct 2024, 10:00 UTC

Earnings

Danaher 3Q Cont Ops EPS $1.12 >DHR

23 Jul 2024, 12:39 UTC

Top News
Earnings

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23 Jul 2024, 10:05 UTC

Earnings

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23 Jul 2024, 10:05 UTC

Earnings

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

28.05% upside

12 Months Forecast

Average 262.71 USD  28.05%

High 300 USD

Low 240 USD

Based on 17 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

13

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

199.78 / 210.26Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

106 / 386 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.